Purpose/Objective(s): The prognostic utility of two nonspecific systemic inflammatory markers, neutrophil-to-lymphocyte ratio (NLR) and plateletto-lymphocyte ratio (PLR), recently demonstrated in other malignancies has yet to be shown in cervical cancer. The aim of this study is to evaluate the prognostic role of pretreatment NLR and PLR in recipients of definitive chemoradiotherapy (ChRT) for cervical cancer. Materials/Methods: In 235 patients given definitive ChRT for histologically confirmed cervical cancer, clinical data and pretreatment complete blood cell counts were analyzed. Patients were stratified by median NLR and PLR. Prognostic and therapeutic ramifications of NLR and PLR were assessed. Results: Median pretreatment NLR and PLR were 3.03 (range, 1.04-13.03) and 133.02 (range, 36.3-518.16), respectively. Both NLR and PLR correlated significantly with tumor size, lymph node metastasis, and treatment response. In addition to NLR and PLR, tumor stage, size, and nodal metastasis were identified by univariate analysis as significant predictors of OS and PFS. By multivariate analysis, independent predictors of OS and PFS were NLR (OS: HR Z 3.322, 95% CI Z 1.905-5.790; PFS: HR Z 3.579, 95% CI Z 2.106-6.082; both P < 0.001) and lymph node metastasis (OS: HR Z 2.620, 95% CI Z 1.706-4.023; PFS: HR Z 2.989, 95% CI Z 1.918-4.378; both P < 0.001); although patient age (HR Z 1.019, 95% CI Z 1.003-1.035; P Z 0.02) was also significantly predictive of OS. Conclusion: Pretreatment NLR and PLR were associated with larger tumors, lymph node metastasis, and poorer therapeutic responses to definitive ChRT. By multivariate analysis, pretreatment NLR and lymph node metastasis were found independently predictive of OS and PFS, whereas patient age was significantly predictive of OS only. In patients with advanced cervical cancer, NLR is a potential biomarker, serving to guide systemic therapy and predict treatment outcomes.
Purpose/Objective(s): Prior studies have investigated the use of quantitative features of pre-treatment positron emission tomography (PET) in predicting treatment outcomes of patients with cervical carcinoma. This study utilizes an expanded set of quantitative imaging parameters from pre-treatment PETs in combination with clinical parameters from an indigent cervical carcinoma population to build a predictive model. Materials/Methods: Eighty-six consecutive patients with stage IB1 to IVA disease treated at our institution from 2009 -2012 were included, with 73 patients utilized to build a distant failure prediction model and 50 patients utilized to build a locoregional failure prediction model. Clinical parameters (age, race, stage, histology, tumor size, and nodal status at diagnosis) were derived from chart review and imaging parameters (12 textural features, 9 intensity features, and 8 geometric features) were derived from pre-treatment PET. Features were selected based on an iterative evaluation of models to maximize sensitivity and specificity rather than using priority scores. Machine learning for the support vector machine to train and validate model performance was conducted using 5 cross validations (80% of patients to train, 10% of patients to test). Segmentation of patients' primary disease on PET was semi-automated, using a manually drawn seed contour to guide the auto-segmentation algorithm. Results: Three models were generated to predict distant failure, and three models were generated to predict locoregional failure. Model 1 for both outcomes was developed using clinical parameters only (age, race, stage, histology, tumor size, and nodal status at diagnosis), Model 2 for both outcomes was developed using clinical parameters plus standard imaging metrics (SUV max, average SUV, metabolic tumor volume, and total lesion glycolysis), and Model 3 for both outcomes was developed using clinical parameters plus an expanded set of imaging parameters (12 textural features, 9 intensity features, and 8 geometric features). The sensitivity, specificity, area under the curve (AUC), and P value for each model is listed in Table 1 . Conclusion: When optimized to maximize sensitivity and specificity, the most complex model using clinical parameters and the expanded set of imaging parameters, Model 3, had the best performance. Given the high specificity of Model 3, it could be used to select patients at high risk for distant or locoregional failure who would benefit from additional outback adjuvant therapy. 
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Utilization of Adjuvant Therapies and Their Impact on Survival for Women With Stage IIIc Endometrial Adenocarcinoma A.T. Wong, 1,2 D. Schwartz, 1,2 J. Safdieh, 1,2 J.P. Weiner, 1,2 K.N. Choi, 2 and D. Schreiber 1,2 ; 1 Veterans Affairs NY Harbor Healthcare System, Brooklyn, NY, 2 SUNY Downstate Medical Center, Brooklyn, NY Purpose/Objective(s): Adjuvant treatment options following surgical staging for women with stage IIIC endometrial carcinoma include chemotherapy (CT) with or without radiation therapy (RT), although the optimal treatment strategy is currently unknown. We used the National Cancer Data Base (NCDB) to investigate the utilization of adjuvant CT and RT for this group of patients and the impact on overall survival (OS) of each of these therapeutic modalities. 
